A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China

Sunshine Guojian Pharmaceutical

Status and phase: Not yet enrolling; Phase 1

Conditions: Atopic Dermatitis

Treatments: Drug: new formulations of 611; Drug: existing formulations of 611

Study type: Interventional

Funder types: Industry

Identifiers

NCT07042113

SSGJ-611-HV-I-02

Details and patient eligibility

About

The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.

Full description

This study is a randomized, open-label, parallel-designed comparative pharmacokinetic study to evaluate the biosimilarity between the formulations of 611.A total of about 180 healthy adult subjects in China were planned to be included, and the qualified subjects were randomly stratified according to the research center, body weight (≥65kg, <65kg), and randomly assigned to the test preparation group and the reference preparation group at a ratio of 1:1, and received a single subcutaneous injection of 300 mg of the experimental drug according to their group. Blood was collected on D1 and D2, D3, D4, D5, D6, D7, D8, D15, D22, D29, D43 and D57 after administration, respectively.

Enrollment: 180 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Willingness to provide written informed consent for the study.
2. Male or female subjects, age 18-45 years older.
3. Within body mass index (BMI) range 19.0 to 26.0 kilograms per square meter (kg/m²).
4. The results of vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray and other examinations during the screening period are normal or judged to be abnormal by the investigator and have no clinical significance.
5. Males and females of non-childbearing potential.

Exclusion criteria

1. History of severe allergies or allergies to 611 and any of its components;
2. Previous or current disease that may affect the safety of the subject's participation in the trial or the in vivo process of the trial drug;
3. Any history of VKC and AKC;
4. History of drug abuse within 2 years prior to screening;
5. Alcoholism within 3 months prior to screening;
6. Those who smoke more than 5 cigarettes per day within 3 months before screening or cannot give up smoking during the period from signing the informed consent of the subject to leaving the group;
7. Those who have consumed more than 1L of strong tea, coffee and/or caffeinated beverages per day within 3 months before screening, and who have ingested chocolate or any food or drink containing caffeine, theophylline, theobromine or alcohol within 48 hours before the study administration;
8. Have active tuberculosis;
9. Presence of active infection requiring systemic treatment prior to screening or dosing;
10. Those who have used any prescription drugs, over-the-counter drugs, vitamin products or Chinese herbal medicines within 4 weeks or 5 half lives (whichever is longer) before dosing, or those who may need to receive other drugs during the trial;
11. Participated in the clinical trial of any drug or device within 3 months or 5 half-lives before dosing;
12. Receipt of any marketed or investigational biologic within 3 months or 5 half lives prior to dosing;
13. Live vaccine or live attenuated vaccine within 2 months prior to dosing or planned administration during the study;
14. Previous use of any IL-4Rα target drugs;
15. Pregnant or lactating females;

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

180 participants in 2 patient groups

Tested preparation group

Experimental group

Description:

Healthy subjects will receive new formulations of 611 300mg once

Treatment:

Drug: new formulations of 611

Reference preparation group

Experimental group

Description:

Healthy subjects will receive existing formulations of 611 300mg once

Treatment:

Drug: existing formulations of 611